AACR 2023 | Improving therapeutic approaches for patients with Ph-like ALL & the importance of disease biology
Sarah Tasian, MD, The Children’s Hospital of Philadelphia, Philadelphia, PA, gives an overview of promising novel strategies for the treatment of patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), including the use of tyrosine kinase inhibitors (TKIs) for patients with ABL-class alterations and ruxolitinib for patients with JAK pathway alterations. Dr Tasian also comments on the importance of understanding the disease biology of Ph-like ALL and translating these findings into clinical practice. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
